Boswellia serrata was associated with acute kidney injury during radiation necrosis treatment
A case report linked high-dose Boswellia serrata use for radiation necrosis with reversible acute kidney injury.
Tag
Worth Attention
A risk score predicted prolonged radiotherapy completion in locally advanced cervical cancer
A score above seven identified patients with treatment beyond 56 days in 53.6% versus 17.8% at lower scores.
Pan-mucosal irradiation did not improve outcomes in head and neck unknown primary cancer
Adding pan-mucosal irradiation did not improve survival or reduce mucosal recurrence compared with nodal-only irradiation in thoroughly staged head and neck unknown primary cancer.
Hypofractionated proton reirradiation showed similar survival to photons in recurrent glioblastoma
Median survival was 8.3 months after proton reirradiation, with 5.6% grade 3–4 radiation necrosis and no survival difference versus photons.
Proton therapy timing was not independently associated with worse rhabdomyosarcoma outcomes
Four-year overall survival was 81.2%, and starting proton therapy at week 14 or later was not independently associated with worse outcomes.
Carbon ion radiotherapy yielded 82.9% two-year locoregional control in stage III non-small cell lung cancer
Carbon ion radiotherapy achieved 82.9% two-year locoregional control, while combined immunotherapy was associated with longer overall survival.
Radiotherapy was associated with longer survival in metastatic cervical cancer
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
No isolated failures in omitted nodal regions with reduced elective irradiation for early oropharyngeal cancer
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
Mid-treatment tumour shrinkage predicted survival in oropharyngeal cancer
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.
Preoperative radiotherapy did not worsen renal function after retroperitoneal sarcoma surgery
Preoperative radiotherapy was not associated with greater renal dysfunction after nephrectomy for retroperitoneal sarcoma during follow-up extending to 80 months.
Prolonged pembrolizumab was associated with longer survival after chemoradiation in non-small cell lung cancer
Longer pembrolizumab exposure after chemoradiation was associated with lower mortality, but immortal time bias prevents causal interpretation.
Ultrahigh dose-rate radiotherapy still requires conformal planning and conservative dose constraints
Normal-tissue sparing with ultrahigh dose-rate radiotherapy remains conditional and cannot replace conformal dosimetry, organ-at-risk constraints, or rigorous quality assurance.
Concurrent chemotherapy improved progression-free but not overall survival in low-volume head and neck cancer
Concurrent chemotherapy improved progression-free survival without a significant overall survival benefit in early primary tumors with low-volume nodal disease.
Preoperative single-fraction and fractionated stereotactic radiotherapy showed similar outcomes after brain metastasis resection
Preoperative single-fraction and fractionated stereotactic radiotherapy produced similarly low composite event rates after resection of brain metastases.
Quality of life remains impaired after chemoradiotherapy for anal squamous cell carcinoma
Patients reported persistently worse quality of life and functioning approximately two years after chemoradiotherapy than matched individuals without cancer.